Link Drug And Diagnostic Policy Pathways To Reach Patients Most Likely To Benefit

The article argues for integrated regulatory and policy frameworks for drugs and their corresponding diagnostics, highlighting how current separate pathways delay treatments and increase costs, with a focus on improving access and precision in patient care.

This Wire brief sits within Fusion42's coverage of Medtech.